ProCE Banner Activity

Management of Mild to Moderate COVID-19 in People Who Are Immunocompromised

PDF

Gain in-depth knowledge on current SARS-CoV-2 trends, risk factors for COVID-19 disease progression, and treatment recommendations based on the latest clinical data and guideline recommendations.

Released: January 23, 2025

Expiration: January 22, 2026

Share

Provided by

Provided by Clinical Care Options, LLC, in partnership with Practicing Clinicians Exchange, ProCE, and the American Academy of Emergency Medicine (AAEM)

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Partners

American Academy of Emergency Medicine (AAEM)

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

ProCE

ProCE Banner

Disclosure

Primary Author

Michele Bartoletti, MD, PhD

Associate Professor of Infectious Diseases
Department of Biomedical Sciences
Humanitas University
Pieve Emanuele (MI), Italy
Head of Infectious Diseases Unit
IRCCS Humanitas Research Hospital
Rozzano (MI), Italy

Michele Bartoletti, MD, PhD, has no relevant financial relationships to disclose.

Cristina Mussini, MD

Full Professor of Infectious Diseases
Division of Infectious Diseases
University of Modena and Reggio Emilia
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: Gilead, Johnson & Johnson, Merck Sharp & Dohme, ViiV.

Martin Witzenrath, MD, FERS

Medical Director
Charite Centrum 12
Internal Medicine & Dermatology
Professor and Chair for Respiratory Medicine and Critical Care
Department of Infectious Disease, Respiratory Medicine and Critical Care
Charite Campus Mitte/Campus Virchow Klinikum/Campus Benjamin Franklin
Charite – University of Berlin
Berlin, Germany

Martin Witzenrath, MD, FERS: researcher: Aptarion, Bayer, Biotest, Boehringer Ingelheim; consultant/advisor/speaker: AstraZeneca, Bayer, Berlin Chemie, Boehringer Ingelheim, Chiesi, Gilead, Hexal, Insmed, Novartis, Pantherna, Pfizer.